Summary

South East Asia swine vaccine market is expected to reach USD 1.7 Billion by 2032 from USD 1.0 billion in 2024, with a CAGR of 6.3% in the forecast period of 2025 to 2032.
Market Segmentation:
South East Asia Swine Vaccine Market, Pathogen (Virus and Bacteria), Indication (Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCV/PCVD), Swine Fever, Foot-And-Mouth Disease (FMD), Porcine Pneumonia, Porcine Parovirus, Glaesserella Parasuis, and Others), Technology (Inactivated Vaccines, Recombinant Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, and Others)), Product (Ingelvac, Porcilis, Improvac, Prevacent, Enterisol, Cirbloc M Hyo, Bioaftogen, Enradin, Yuan Ke Xin, Circovac, Hyogen, Salmoporc, Ecoporc Shiga, Parvoruvax, Enteroporc Coli Ac, Navet-Asfvac & Avac Asf Live, Coglapix, Progressis, Ruilan, Vepured, Suigen, Shield, Ruifute-Wang, Refute, Ruiyuanshu, Clear The False Spirit, and Others), Demographic (Piglet and Adult), Route of Administration (Intramuscular, Subcutaneous, and Others), Distribution Channel (Hospitals and Clinics, Retail Pharmacies, E-commerce Platforms, and Others), Country (China, Thailand, Vietnam, Philippines, South Korea, Taiwan, and Rest of South East Asia) - Industry Trends and Forecast to 2032

Overview of South East Asia Swine Vaccine Market Dynamics:

Driver

• Rising incidence of swine diseases

Restraint

• Complexity of vaccination protocols and factors affecting efficacy as a restraint
Opportunity

• Urgent need for enhanced disease prevention in swine production


Market Players

The key market players for south east Asia swine vaccine market are listed below:

• Boehringer Ingelheim International GmbH

• Merck & Co., Inc.

• Zoetis Inc.

• Ceva

• Pulike Biological Engineering Co., Ltd.

• Elanco Animal Health Incorporated

• Biogénesis Bagó S.A.

• HIPRA, S.A.

• Jinyu Bio-Technology Co., Ltd.

• Shanghai Shen Lian Biomedical Corporation

• China Animal Husbandry Industry Co., Ltd.

• ESCO ASTER PTE. LTD.

• Shanghai Haili Biotechnology Co., Ltd.

• AVAC Vietnam Joint Stock Company

• Bimeda Biologicals Ltd.

• Harbin Harvac Biotechnology Co., Ltd.

• Virbac S.A.
•

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF THE SOUTH EAST ASIA SWINE VACCINE MARKET 17
1.4 LIMITATIONS 19
1.5 MARKETS COVERED 19
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 23
2.4 CURRENCY AND PRICING 23
2.5 DBMR TRIPOD DATA VALIDATION MODEL 24
2.6 MULTIVARIATE MODELLING 27
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.8 DBMR MARKET POSITION GRID 29
2.9 SECONDARY SOURCES 31
2.10 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 37
4.1 PESTAL ANALYSIS 38
4.2 PORTERS FIVE FORCES ANALYSIS 39
4.3 DRUG TREATMENT RATE BY MATURED MARKETS 40
4.4 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 40
4.5 PATIENT FLOW DIAGRAM 41
4.6 KEY PRICING STRATEGIES 42
4.7 KEY PATIENT ENROLLMENT STRATEGIES 43
4.8 MARKETED DRUG ANALYSIS 44
4.9 AVERAGE PRICED PAID FOR A VACCINE DOSE 48
4.10 HEALTHCARE TARIFFS IMPACT ANALYSIS 49
4.10.1 OVERVIEW 49
4.10.2 TARIFF STRUCTURES 49
4.10.2.1 GLOBAL VS. REGIONAL TARIFF STRUCTURES 49
4.10.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS 49
4.10.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES 49
4.10.2.4 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS 49
4.10.2.5 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION 49
4.10.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS 49
4.10.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS 49
4.10.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS 50
4.10.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS 50
4.10.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS 50
4.10.4.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 50
4.10.4.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE 50
4.10.4.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM 50
4.10.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS 50
4.10.5.1 WTO REGULATIONS ON HEALTHCARE TARIFFS 50
4.10.5.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 50
4.10.5.3 ROLE OF FREE TRADE AGREEMENTS (FTAs) IN REDUCING TARIFFS 50
4.10.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 50
4.10.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 50
5 EPIDEMIOLOGICAL OVERVIEW OF KEY SWINE DISEASES IN THE SOUTH EAST ASIA (SEA) SWINE VACCINE MARKET: 51
5.1 PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) 51
5.2 PORCINE CIRCOVIRUS ASSOCIATED DISEASE (PCV/PCVD) 51
5.3 FOOT-AND-MOUTH DISEASE (FMD) 51
5.4 AFRICAN SWINE FEVER (ASF) 51
5.5 CLASSICAL SWINE FEVER (CSF) 51
5.6 PORCINE PARVOVIRUS (PPV) 52
5.7 PORCINE PNEUMONIA 52
5.8 GLAESSERELLA PARASUIS (GLÄSSER’S DISEASE) 52
6 MARKET OVERVIEW 54
6.1 DRIVER 56
6.1.1 RISING INCIDENCE OF SWINE DISEASES. 56
6.1.2 HIGHER PORK CONSUMPTION ACROSS SOUTHEAST ASIAN COUNTRIES. 56
6.1.3 INCREASE IN PORK EXPORTS FROM SOUTHEAST ASIA. 57
6.2 RESTRAINT 58
6.2.1 COMPLEXITY OF VACCINATION PROTOCOLS AND FACTORS AFFECTING EFFICACY AS A RESTRAINT 58
6.2.2 LACK OF ADEQUATE COLD CHAIN LOGISTICS. 58
6.3 OPPORTUNITIES 59
6.3.1 INNOVATIONS IN VACCINE TECHNOLOGIES 59
6.3.2 URGENT NEED FOR ENHANCED DISEASE PREVENTION IN SWINE PRODUCTION 59
6.3.3 IMPROVED DIAGNOSTICS AND MONITORING 60
6.4 CHALLENGES 61
6.4.1 COMPETITION FROM ALTERNATIVE DISEASE MANAGEMENT STRATEGIES 61
6.4.2 LOW INVESTMENT IN DISEASE SURVEILLANCE FOR SWINE IN ASIA 61
7 SOUTH EAST ASIA SWINE VACCINES MARKET, BY TECHNOLOGY 63
7.1 OVERVIEW 64
7.2 INACTIVATED VACCINES 67
7.3 RECOMBINANT VACCINES 67
7.4 LIVE ATTENUATED VACCINES 67
7.5 TOXOID VACCINES 67
7.6 OTHERS 67
8 SOUTH EAST ASIA SWINE VACCINES MARKET, BY PRODUCT 68
8.1 OVERVIEW 69
8.2 INGELVAC 75
8.2.1 PARVORUVAX 75
8.2.2 ENTEROPORC COLI AC 75
8.2.3 NAVET-ASFVAC & AVAC ASF LIVE 75
8.2.4 COGLAPIX 75
8.3 PORCILIS 76
8.3.1 CSF LIVE 76
8.3.2 APP 76
8.3.3 AR-T 76
8.3.4 GLASSER 76
8.3.5 PARVO 76
8.3.6 PORCOLI DF 76
8.3.7 BEGONIA 76
8.4 IMPROVAC 76
8.5 PREVACENT 76
8.6 ENTERISOL 77
8.7 CIRBLOC M HYO 77
8.8 BIOAFTOGEN 77
8.9 ENRADIN 77
8.10 YUAN KE XIN 77
8.11 CIRCOVAC 77
8.12 HYOGEN 77
8.13 SALMOPORC 77
8.14 ECOPORC 77
8.15 PARVORUVAX 77
8.16 ENTEROPORC COLI AC 77
8.17 NAVET-ASFVAC & AVAC ASF LIVE 78
8.18 COGLAPIX 78
8.19 PROGRESSIS 78
8.20 RUILAN 78
8.21 VEPURED 78
8.22 SUIGEN 78
8.23 SHIELD 78
8.23.1 PARVO SHIELD 79
8.23.2 PARA SHIELD 79
8.23.3 RHINI SHIELD 79
8.23.4 PILI SHIELD 79
8.24 RUIFUTE-WANG 79
8.25 REFUTE 79
8.26 RUIYUANSHU 79
8.27 CLEAR THE FALSE SPIRIT 79
8.28 OTHERS 79
9 SOUTH EAST ASIA SWINE VACCINES MARKET, BY PATHOGEN 80
9.1 OVERVIEW 81
9.2 VIRUS 84
9.3 BACTERIA 84
10 SOUTH EAST ASIA SWINE VACCINES MARKET, BY INDICATION 85
10.1 OVERVIEW 86
10.2 PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) 89
10.3 PORCINE CIRCOVIRUS ASSOCIATED DISEASE (PCV/PCVD) 89
10.4 SWINE FEVER 89
10.4.1 CLASSICAL SWINE FEVER (CSF) 89
10.4.2 AFRICAN SWINE FEVER (ASF) 89
10.5 FOOT-AND-MOUTH DISEASE (FMD) 89
10.6 PORCINE PNEUMONIA 89
10.7 PORCINE PAROVIRUS 89
10.8 GLAESSERELLA PARASUIS 90
10.9 OTHERS 90
11 SOUTH EAST ASIA SWINE VACCINE MARKET, BY DEMOGRAPHIC 91
11.1 OVERVIEW 92
11.2 PIGLET 95
11.3 ADULT 95
 
12 SOUTH EAST ASIA SWINE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 96
12.1 OVERVIEW 97
12.2 INTRAMUSCULAR 100
12.3 SUBCUTANEOUS 100
12.4 OTHERS 100
13 SOUTH EAST ASIA SWINE VACCINES MARKET, BY DISTRIBUTION CHANNEL 101
13.1 OVERVIEW 102
13.2 HOSPITALS AND CLINICS 105
13.3 RETAIL PHARMACIES 105
13.4 E-COMMERCE PLATFORMS 105
13.5 OTHERS 105
14 SOUTH EAST ASIA SWINE VACCINES MARKET, BY COUNTRY 106
14.1 SOUTH EAST ASIA 106
14.1.1 CHINA 114
14.1.2 THAILAND 118
14.1.3 VIETNAM 123
14.1.4 PHILIPPINES 128
14.1.5 SOUTH KOREA 133
14.1.6 TAIWAN 138
14.1.7 REST OF SOUTH EAST ASIA 143
15 SOUTH EAST ASIA SWINE VACCINES MARKET: COMPANY LANDSCAPE 144
15.1 COMPANY SHARE ANALYSIS: SOUTH EAST ASIA 144
16 SWOT ANALYSIS 145
17 COMPANY PROFILES 146
17.1 BOEHRINGER INGELHEIM GMBH 146
17.1.1 COMPANY SNAPSHOT 146
17.1.2 REVENUE ANALYSIS 146
17.1.3 PRODUCT PORTFOLIO 147
17.1.4 RECENT DEVELOPMENT 148
17.2 MERCK & CO., INC. 150
17.2.1 COMPANY SNAPSHOT 150
17.2.2 REVENUE ANALYSIS 150
17.2.3 PRODUCT PORTFOLIO 151
17.2.4 RECENT DEVELOPMENT/NEWS 155
 
17.3 ZOETIS SERVICES LLC. 156
17.3.1 COMPANY SNAPSHOT 156
17.3.2 REVENUE ANALYSIS 156
17.3.3 PRODUCT PORTFOLIO 157
17.3.4 RECENT DEVELOPMENT 158
17.4 JINYU BIOTECHNOLOGY CO., LTD 159
17.4.1 COMPANY SNAPSHOT 159
17.4.2 REVENUE ANALYSIS 159
17.4.3 PRODUCT PORTFOLIO 159
17.4.4 RECENT DEVELOPMENT 159
17.5 CEVA 160
17.5.1 COMPANY SNAPSHOT 160
17.5.2 PRODUCT PORTFOLIO 160
17.5.3 RECENT DEVELOPMENT 161
17.6 BIMEDA BIOLOGICALS 162
17.6.1 COMPANY SNAPSHOT 162
17.6.2 PRODUCT PORTFOLIO 162
17.6.3 RECENT UPDATES 162
17.7 BIMEDA BIOLOGICALS 163
17.7.1 COMPANY SNAPSHOT 163
17.7.2 PRODUCT PORTFOLIO 163
17.7.3 RECENT UPDATES 163
17.8 BIOGÉNESIS BAGÓ 164
17.8.1 COMPANY SNAPSHOT 164
17.8.2 PRODUCT PORTFOLIO 164
17.8.3 RECENT UPDATES 165
17.9 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. 166
17.9.1 COMPANY SNAPSHOT 166
17.9.2 REVENUE ANALYSIS 166
17.9.3 PRODUCT PORTFOLIO 166
17.9.4 RECENT DEVELOPMENT 166
17.10 ELANCO 167
17.10.1 COMPANY SNAPSHOT 167
17.10.2 REVENUE ANALYSIS 168
17.10.3 PRODUCT PORTFOLIO 168
17.10.4 RECENT DEVELOPMENT/NEWS 168
17.11 ESCO ASTER PTE. LTD. 169
17.11.1 COMPANY SNAPSHOT 169
17.11.2 PRODUCT PORTFOLIO 169
17.11.3 RECENT UPDATES 170
17.12 HARBIN HARVAC BIOTECHNOLOGY CO. LTD 171
17.12.1 COMPANY SNAPSHOT 171
17.12.2 PRODUCT PORTFOLIO 171
17.12.3 RECENT DEVELOPMENT 172
17.13 HIPRA 173
17.13.1 COMPANY SNAPSHOT 173
17.13.2 PRODUCT PORTFOLIO 173
17.13.3 RECENT UPDATES 175
17.14 PULIKE BIOLOGICAL ENGINEERING 176
17.14.1 COMPANY SNAPSHOT 176
17.14.2 REVENUE ANALYSIS 176
17.14.3 PRODUCT PORTFOLIO 177
17.14.4 RECENT DEVELOPMENT 177
17.15 SHANGHAI SHEN LIAN BIOMEDICAL CORPORATION 178
17.15.1 COMPANY SNAPSHOT 178
17.15.2 PRODUCT PORTFOLIO 178
17.15.3 RECENT DEVELOPMENT 179
17.16 SHANGHAI HAILI BIOTECHNOLOGY CO., LTD. 180
17.16.1 COMPANY SNAPSHOT 180
17.16.2 PRODUCT PORTFOLIO 180
17.16.3 RECENT UPDATES 181
17.17 VIRBAC 182
17.17.1 COMPANY SNAPSHOT 182
17.17.2 REVENUE ANALYSIS 183
17.17.3 PRODUCT PORTFOLIO 183
17.17.4 RECENT DEVELOPMENT 184
18 QUESTIONNAIRE 185
19 RELATED REPORTS 189